Biocon Q1 PAT climbs 71% YoY to Rs 144 cr

Image
Capital Market
Last Updated : Jul 28 2022 | 10:16 AM IST

The biotech company's consolidated net profit surged 71.1% to Rs 144.40 crore on 21.5% jump in revenue from operations to Rs 2,139.50 crore in Q1 FY23 over Q1 FY22.

Total revenue grew 22.7% to Rs 2,217.40 crore in Q1 FY23 as against Rs 1,807.80 crore posted in Q1 FY22. Profit before tax stood at Rs 196.90 crore in Q1 FY23, up 18.8% from Rs 165.70 crore recorded in the corresponding quarter previous year.

Consolidated EBITDA rose 9% to Rs 478 crore in Q1 FY23 as compared to Rs 437 crore reported in Q1 FY22. EBITDA margin decreased to 22% in Q1 FY23 as against 24% recorded in the same period last year. Core EBITDA jumped 25% to Rs 660 crore in the first quarter from Rs 530 crore posted in Q1 FY22.

Net profit margins increased to 7% in Q1 FY23 as compared to 5% in Q1 FY22. Gross research & development (R&D) spend soared 64% to Rs 223 crore in Q1 FY22 as against Rs 136 crore posted in the same period a year ago.

Revenue from Generics was Rs 580 crore (up 19% YoY), Biosimilars revenue stood at Rs 977 crore (up 29% YoY) and revenue from Research services was Rs 645 crore (up 8% YoY).

Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, said, "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics (19%). Core EBITDA grew 25% and margin improved to 31% compared to 30% in Q1FY22 and Net Profit grew 71% to Rs 144 crore. Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. R&D investments increased significantly by Rs 87 crore this quarter reflecting pipeline progression to deliver future growth. All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the COVID-19 pandemic."

Biocon is a global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune.

Shares of Biocon were down 4.66% to Rs 307.75 on the BSE.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 28 2022 | 9:53 AM IST

Next Story